Takeda plans Japan filing. Takeda stock gets 10.2-month survival data
Published on 10/26/2026 at 09:08 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSOncology filing plans and key dates
- On October 25, 2026, Takeda reported 10.2 months of median overall survival versus 6.9 months for chemotherapy.
- Progression-free survival reached 7.1 months versus 3.1 months in the independently reviewed study.
- Takeda stock last stood at EUR 16.80 on Tradegate on October 9, 2026 at 8:28 a.m. CEST.
Takeda Pharmaceutical plans to seek Japanese approval next year for its gastric cancer drug TAK-921 after a late-stage study showed median overall survival of 10.2 months versus 6.9 months for chemotherapy, Reuters reported on October 25, 2026. For Takeda stock, the result adds a concrete development milestone to the company's oncology strategy.
Survival data strengthen the filing case
The same trial produced median progression-free survival of 7.1 months with TAK-921 versus 3.1 months in the control group, according to Reuters. The study enrolled 464 patients in Japan and China, and the drug's serious side-effect rate was 47 percent versus 56 percent for chemotherapy. The results came from patients who had received at least two earlier treatments.
What changed across three events
On July 30, 2026, Takeda reported first-quarter revenue of USD 7.65 billion against a USD 7.06 billion estimate, according to Benzinga. On October 14, 2026, detailed TAK-881 data showed a 50 percent reduction in infusion volume and a 56.2-minute reduction in one-site infusion time, MarketScreener reported. On October 25, 2026, the TAK-921 data supplied the latest oncology milestone with the 10.2-month survival result.
When is the next reporting date
Takeda's investor-relations page schedules the fiscal 2026 second-quarter earnings announcement for October 29, 2026, with a webcast later that day in Japan time, according to Takeda. That release should provide the next quantified test of product launches, pipeline progress and the company's full-year outlook.
Stock context for investors
The latest structured market snapshot placed Takeda's market capitalization at USD 64.4 billion on October 23, 2026. Its primary listing is on the NYSE, while the company also trades in Tokyo; the euro quotation gives German investors a separate local reference.
The last available euro price stood at EUR 16.80 on Tradegate on October 9, 2026 at 8:28 a.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Takeda stock.
Takeda stock key data
- Company: Takeda Pharmaceutical Company Limited
- ISIN: US8740602052
- Ticker: TAK
- Primary exchange: NYSE
- Last euro price on Tradegate (as of October 9, 2026, 8:28 a.m. CEST): EUR 16.80
- Market capitalization: USD 64.4 billion (as of October 23, 2026)
- Sector / Industry: Healthcare / Drug Manufacturers - Specialty and Generic
Market context: Market report Nikkei 225.
